Trexquant Investment LP boosted its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 155.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 298,334 shares of the company's stock after purchasing an additional 181,532 shares during the quarter. Trexquant Investment LP owned approximately 0.08% of Bausch Health Companies worth $2,405,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in BHC. Geode Capital Management LLC increased its stake in shares of Bausch Health Companies by 12.5% in the fourth quarter. Geode Capital Management LLC now owns 715,570 shares of the company's stock worth $5,767,000 after buying an additional 79,488 shares during the last quarter. Franklin Resources Inc. grew its holdings in Bausch Health Companies by 1.1% during the 4th quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock worth $42,855,000 after acquiring an additional 56,446 shares in the last quarter. O Shaughnessy Asset Management LLC increased its position in shares of Bausch Health Companies by 989.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 611,890 shares of the company's stock worth $4,940,000 after purchasing an additional 555,709 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Bausch Health Companies by 46.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after purchasing an additional 1,510,445 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Bausch Health Companies during the fourth quarter worth about $141,000. 78.65% of the stock is owned by institutional investors and hedge funds.
Bausch Health Companies Stock Down 1.0 %
Shares of NYSE:BHC traded down $0.05 during trading on Friday, hitting $4.33. 2,276,584 shares of the company traded hands, compared to its average volume of 2,693,855. The business's fifty day moving average is $6.53 and its 200-day moving average is $7.54. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -36.04, a PEG ratio of 0.37 and a beta of 0.43. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $9.85.
Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. On average, analysts forecast that Bausch Health Companies Inc. will post 4.41 EPS for the current year.
Analyst Ratings Changes
Several analysts recently weighed in on the company. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada decreased their target price on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating for the company in a research report on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.17.
Check Out Our Latest Stock Report on BHC
Bausch Health Companies Company Profile
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
